MedWatch

Analyst: Novo’s heavy artillery

The European approval of Novo Nordisk’s long-acting insulin Tresiba is not a great surprise to analyst Søren Løntoft Hansen. He highlights one aspect of the approval, which will help the Danes in the battle with rival Sanofi.

Foto: Novo Nordisk/PR

The news about the EU commission’s approval of Tresiba was not a huge surprise, as the drug had already been recommended by the medicines committee CHMP under the EMA.

“But it is obviously positive news for Novo Nordisk. Now they have final approval in Europe and can commence the battle with Lantus, the best selling insulin drug in Europe and the rest of the world. It looks like they will have a favourable label, where some of the advantages over Lantus are highlighted. Among these are fewer hypoglycaemia incidents and more powerful and more flexible dosage,” analyst Søren Løntoft Hansen tells Medwatch.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier